Cogent Biosciences Inc COGT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $38.30
- Day Range
- $38.48–39.72
- 52-Week Range
- $10.37–43.65
- Bid/Ask
- $39.62 / $39.81
- Shares Outstanding
- 170.87M
- Market Cap
- $6.71B
- Volume/Avg
- 307,270 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 258
- Website
- https://www.cogentbio.com
Valuation
|
Metric
|
COGT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 12.29 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
COGT
|
|---|---|
Quick Ratio | 14.94 |
Current Ratio | 15.14 |
Interest Coverage | −86.40 |
Quick Ratio
COGT
Profitability
|
Metric
|
COGT
|
|---|---|
Return on Assets (Normalized) | −52.06% |
Return on Equity (Normalized) | −101.96% |
Return on Invested Capital (Normalized) | −60.96% |
Return on Assets
COGT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Px@><$$ | LOCK|P@bQ! | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Zq>VFJ? | LOCK|S@z$ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|&!<@P?$ | LOCK|^P | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|XH^q<DR | LOCK|## | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|TX&Y#N& | LOCK|SdT^D | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|W$T&#%$h | LOCK|QZ$z> | $25B | |||
| Moderna Inc
MRNA
| LOCK|GMCWxq | LOCK|WtS | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|>z@fNF | LOCK|H@ | $23B | |||
| Incyte Corp
INCY
| LOCK|#%#h#<# | LOCK|^H! | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|D<H<pv | LOCK|^w | $16B |
United States